ADAMTS13 rs121908478: What Your Genotype Means
The rs121908478 variant is a rare genetic change located within the ADAMTS13 gene. It is primarily recognized in clinical research for its association with hereditary thrombotic thrombocytopenic purpura, a condition characterized by the body's inability to properly regulate blood clotting.
What each genotype means
Typical ADAMTS13 function
This is the common, wild-type genotype for this position in the ADAMTS13 gene. Individuals with this genotype do not carry the specific pathogenic variant associated with Upshaw-Schulman syndrome.
This is the most common genotype found in the general population.
Carrier of rare variant
This genotype indicates you carry one copy of the rare variant associated with ADAMTS13-related conditions. Because this condition is typically inherited in an autosomal recessive manner, carriers are generally asymptomatic, though you should consult with a genetic counselor regarding family planning.
This heterozygous genotype is rare in the general population.
Associated with pathogenic risk
This genotype is classified as pathogenic and is linked to Upshaw-Schulman syndrome, a hereditary form of thrombotic thrombocytopenic purpura. If you have this result, it is essential to discuss these findings with a hematologist or medical geneticist to understand your clinical risk and management options.
This homozygous genotype is extremely rare in the general population.
Understanding the rs121908478 Variant
The rs121908478 variant is a specific alteration in the DNA sequence of the ADAMTS13 gene, which is located on chromosome 9. In genetic databases, this variant is identified by its reference SNP cluster ID, rs121908478. It represents a change where a cytosine (C) base is replaced by a thymine (T) base at a specific position in the genome. Because this variant is rare, it is not typically found in the general population at high frequencies. Geneticists study such variants to understand how small changes in our DNA code can impact the production or function of essential proteins. When a variant occurs within a protein-coding gene like ADAMTS13, it has the potential to alter the structure of the resulting enzyme, which may lead to downstream effects on physiological processes such as blood coagulation.
The Role of the ADAMTS13 Gene
The ADAMTS13 gene provides the blueprint for an enzyme known as ADAMTS13, or von Willebrand factor-cleaving protease. This enzyme acts like a pair of molecular scissors, specifically designed to cut von Willebrand factor (VWF), a large protein that promotes blood clotting. Under normal conditions, ADAMTS13 keeps VWF in check, preventing it from becoming too long and sticky, which could otherwise lead to the formation of dangerous, unintended blood clots throughout the body. The enzyme is primarily produced in the liver and circulates in the bloodstream, where it constantly monitors and regulates the size of VWF molecules. When the ADAMTS13 gene contains certain pathogenic variants, the body may produce a non-functional or deficient enzyme, disrupting this delicate balance and increasing the risk of clot-related health complications.
Clinical Associations and Evidence
Research has linked the rs121908478 variant to Upshaw-Schulman syndrome, a form of hereditary thrombotic thrombocytopenic purpura (TTP). In individuals who inherit this variant, the resulting deficiency in ADAMTS13 activity can lead to the formation of microscopic clots in small blood vessels. These clots consume platelets, which are necessary for normal clotting, and can damage red blood cells as they pass through the obstructed vessels. The evidence for this association is considered significant in clinical genetics, as it is categorized as a pathogenic variant in databases like ClinVar. It is important to note that while this variant is associated with specific clinical outcomes, the presence of a genetic variant does not guarantee the development of a disease. Clinical diagnosis of TTP involves a combination of laboratory testing, symptom evaluation, and medical history, which should always be managed by a qualified healthcare professional.
Population Frequency and Distribution
The rs121908478 variant is classified as rare across global populations. Because it is not a common polymorphism, it is not typically tracked in the same way as variants that are widespread in the general public. Most individuals do not carry this specific change. Its rarity means that it is primarily identified in clinical settings, often through family studies or diagnostic testing for individuals presenting with symptoms of TTP. Because the variant is so infrequent, large-scale population studies often report it at very low frequencies or not at all, depending on the ancestry of the cohort being studied. This scarcity underscores the importance of clinical genetic counseling for individuals who may be identified as carriers, as the implications are highly specific to the individual's family history and health status.
Navigating Genetic Information
If you have received information about the rs121908478 variant, it is essential to understand that this data is for educational purposes and does not constitute a medical diagnosis. Genetic variants can have complex effects, and their clinical significance can vary based on other genetic factors and environmental influences. You cannot use this information to self-diagnose or make decisions about medical treatments. If you are concerned about your genetic health or a family history of blood disorders, the most appropriate step is to consult with a genetic counselor or a hematologist. These professionals can provide context, explain the results of any genetic testing, and discuss whether further clinical evaluation is necessary. Always rely on personalized medical advice from your healthcare provider rather than general information found in public databases or online resources.
How common is this variant?
The rs121908478 variant is considered rare in the general population, with very low frequency across all major ancestral groups.
Frequently asked questions
What is the rs121908478 variant?
The rs121908478 variant is a rare genetic change in the ADAMTS13 gene. It is associated with a deficiency in the ADAMTS13 enzyme, which is responsible for regulating blood clotting.
Is rs121908478 linked to a specific disease?
Yes, this variant is linked to hereditary thrombotic thrombocytopenic purpura, also known as Upshaw-Schulman syndrome. This condition involves the formation of small blood clots throughout the body.
Should I be worried if I have this variant?
Genetic variants are only one part of your overall health picture. If you are concerned about your results, you should discuss them with a doctor or a genetic counselor who can interpret the findings in the context of your personal health.
How is this variant detected?
This variant is typically detected through clinical genetic testing, often ordered by a specialist when a patient shows symptoms of a blood clotting disorder. It is not usually included in standard wellness-focused genetic screening panels.
Sources & further reading
Educational information only, last refreshed 9/19/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121908478?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in ADAMTS13
This pathogenic variant is linked to Upshaw-Schulman syndrome, which can cause severe complications during pregnancy.
This variant is a pathogenic deletion associated with Upshaw-Schulman syndrome, a rare form of thrombotic thrombocytopenic purpura.
This variant is associated with Upshaw-Schulman syndrome, a rare hereditary form of thrombotic thrombocytopenic purpura.
Variants in this gene are linked to protein activity levels that may impact dermal microvasculature and skin health.